Literature DB >> 3486018

Eosinophil differentiating activity in sera of patients with AIDS under recombinant IL-2 substitution.

P Kern, M Dietrich.   

Abstract

An increase in circulating eosinophils was observed in patients with AIDS or ARC who were substituted for a period of 14 days with exogenous recombinant IL-2 in the context of a Phase I/II study. IL-2 exerts a broad range of biological properties and enhances the production of a variety of other cytokines, i.e., factors for haemopoietic cell growth and differentiation. After having excluded a direct effect of r IL-2 on haemopoietic precursor cells in semi-solid agar cultures, we developed a liquid culture system and studied the effect of patients' sera collected at different time intervals before, during and after r IL-2 substitution on cell differentiation of normal human bone-marrow cells in vitro. Patients' eosinophilia was preceded by a detectable activity in the sera which induced light-density, non-adherent bone-marrow cells to differentiate into the eosinophil lineage and was assessed by the presence of eosinophil primary granules or Luxol-fast blue positive granules. Thus, these in vitro data suggest the presence of circulating mediator(s) enhancing eosinophil production and differentiation in response to in vivo substitution of r IL-2.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3486018     DOI: 10.1007/BF00321085

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  18 in total

1.  Endogenous regulation of macrophage proliferative expansion by colony-stimulating factor-induced interferon.

Authors:  R N Moore; H S Larsen; D W Horohov; B T Rouse
Journal:  Science       Date:  1984-01-13       Impact factor: 47.728

2.  Acid-labile human leukocyte interferon in homosexual men with Kaposi's sarcoma and lymphadenopathy.

Authors:  E DeStefano; R M Friedman; A E Friedman-Kien; J J Goedert; D Henriksen; O T Preble; J A Sonnabend; J Vilcek
Journal:  J Infect Dis       Date:  1982-10       Impact factor: 5.226

3.  Myeloid differentiation of human blood mononuclear cells in liquid culture.

Authors:  J Goldberg; L A McGuire; W J Williams
Journal:  Blood       Date:  1981-03       Impact factor: 22.113

4.  In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

Authors:  M T Lotze; L W Frana; S O Sharrow; R J Robb; S A Rosenberg
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

5.  Preliminary clinical observations with recombinant interleukin-2 in patients with AIDS or LAS.

Authors:  P Kern; J Toy; M Dietrich
Journal:  Blut       Date:  1985-01

6.  Regulation of human granulocyte function by products derived from murine tumors.

Authors:  M A Vadas; I Clark-Lewis
Journal:  Exp Hematol       Date:  1985-02       Impact factor: 3.084

7.  OKT3 monoclonal antibody induces production of colony-stimulating factor(s) for granulocytes and macrophages in cultures of human T lymphocytes and adherent cells.

Authors:  E Platzer; B Y Rubin; L Lu; K Welte; H E Broxmeyer; M A Moore
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

8.  Effects of systemic in vivo interleukin-2 (IL-2) reconstitution in patients with acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC) on phenotypes and functions of peripheral blood mononuclear cells (PBMC).

Authors:  M Ernst; P Kern; H D Flad; A J Ulmer
Journal:  J Clin Immunol       Date:  1986-03       Impact factor: 8.317

9.  Identification of a lymphokine that stimulates eosinophil differentiation in vitro. Its relationship to interleukin 3, and functional properties of eosinophils produced in cultures.

Authors:  C J Sanderson; D J Warren; M Strath
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

10.  Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.

Authors:  A Mazumder; S A Rosenberg
Journal:  J Exp Med       Date:  1984-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.